PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Trigger-First LLM Review Cuts ADR Workload; Fine-Tuning Curbs False Positives

adverse drug reactionpharmacovigilanceelectronic triggerlarge language modelQwen3LoRA fine-tuningmedication safetyhospital-prepared herbal formulationQingyanhou Mixtureretrospective cohortdiagnostic accuracyEHR surveillance Medication Safety

Background Information

LLM-assisted ADR surveillance boosts precision while cutting review workload.

Improving adverse drug reaction (ADR) detection can enhance medication safety by reducing false positives and unnecessary reviews. The trigger-first method achieved 100% sensitivity and 98.25% specificity; LoRA fine-tuning further improved specificity to 94.96%. Although promising, these tools require pharmacist oversight and cannot replace human review entirely. Limited by small sample size. Trigger-first and LoRA fine-tuning can streamline ADR surveillance but require pharmacist oversight.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Liao C, Lai X, Chen W, He J, Yu X

Citation: Liao C, Lai X, Chen W, et al. Trigger-first large language model-assisted adverse drug reaction surveillance: A pharmacist-supervised retrospective cohort study. Exploratory research in clinical and social pharmacy. 2026;24:100866. doi:10.1016/j.rcsop.2026.100866

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.